Predicting mortality from cardiogenic shock
Fundació Institut d’Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP), Spain
Myocardial infarction-derived conditions affect approximately 43 million people worldwide every year. In 8-10 % of cases, the patient develops cardiogenic shock (CS) with mortality rates as high as 50 %.
Currently, clinicians do not have effective prognostic tools to manage these emergencies, leaving them with no real information about potential clinical evolution.
The researchers have identified 4 proteins with which they can predict the outcome of a patient suffering from CS. These results were used to develop a chemiluminescence assay (CLIA), which could help clinicians to optimize treatments and make quick decisions to save the lives of their patients. With this project, they aim to carry out clinical studies comparing their method to the current gold standard as well as advance in the IP protection, the roadmap for regulatory approval and preparation of the commercialization plan.